title: [Inhibition effects of octreotide on the growth of hepatocellular carcinoma in vitro and in vivo].
abstract: OBJECTIVE
  To investigate the effects of somatostatin analogue octreotide on the proliferation and apoptosis of human hepatocellular carcinoma (HCC) cell line as well as the growth of HCC xenografts in nude mice.
  
  
  METHODS
  The effects of octreotide on the proliferation and apoptosis of SMMC-7721 HCC cells was measured by 3H-thymidine incorporation into DNA and the TdT-mediated dUTP nick end labeling assay (TUNEL) or flow cytometric assay separately. Nude mice bearing xenografts of the cell line were treated with octreotide or saline as a control daily until eight weeks after tumor implantation.
  
  
  RESULTS
  Incubation with octreotide decreased 3H-thymidine incorporation into DNA of SMMC-7721 cells by approximately 50% at a concentration of 1 mumol/L. The inhibit effect of octreotide showed a concentration dependence. After 96 h incubation, total cell count was decreased 52.2% compared with control. When cells were treated by octreotide at 1 x 10(-6) mol/L for 24 hours, the apoptosis rates was (15.2 +/- 2.4)%. At necropsy, in mice given octreotide, the mean tumor weight were significantly lower than that of control group (0.27 +/- 0.05 vs 0.85 +/- 0.37, P < 0.01). The inhibition rate of tumor in vivo at 2 months was 68.2%.
  
  
  CONCLUSIONS
  Octreotide is effective in inhibiting growth of HCC both in vivo and in vitro significantly. The mechanisms of antineoplastic effect action may involved in inhibiting DNA synthesize and inducing apoptosis of tumor cells.
authors.affiliation: Department of Gastroenterology, First Hospital, Chongqing University of Medical Sciences, Chongqing, 400016 China.
authors.forename: C
authors.initials: C
authors.lastname: Wang
authors.forename: C
authors.initials: C
authors.lastname: Tang
authors.forename: L
authors.initials: L
authors.lastname: Tang
mesh_terms: D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology; D002455:Cell Division / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D020287:In Situ Nick-End Labeling; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D015282:Octreotide / Q000494:pharmacology* / Q000627:therapeutic use; D013997:Time Factors; D014407:Tumor Cells, Cultured; D023041:Xenograft Model Antitumor Assays
chemical_list: D018931:Antineoplastic Agents, Hormonal; D015282:Octreotide